Curasight is a Danish biotech company with two core radiopharmaceutical products. The uTRACE® is for cancer diagnostics and the uTREAT® is for treatment of cancer. Due to R&D progress within nuclear medicine, interest in the radiopharmaceuticals space has skyrocketed recently. M&A activity in the field has increased and radiotherapy was a hot topic at the recent ASCO meeting. Curasight is on track to reap the benefits of this emerging trend.

Länk till analysen